Perales, Oscar http://orcid.org/0000-0003-0800-4252
Jilaveanu, Lucia http://orcid.org/0000-0001-8900-5083
Adeniran, Adebowale http://orcid.org/0000-0001-9820-632X
Su, David G. http://orcid.org/0000-0002-8693-612X
Hurwitz, Michael http://orcid.org/0000-0002-1326-7308
Braun, David A. http://orcid.org/0000-0003-4543-5553
Kluger, Harriet M. http://orcid.org/0000-0002-4932-9873
Schoenfeld, David A. http://orcid.org/0000-0002-5202-3744
Funding for this research was provided by:
National Institutes of Health (R01 CA269286, P50 CA121974, K12CA215110)
Article History
Received: 5 June 2024
Accepted: 5 July 2024
First Online: 6 August 2024
Declarations
:
: HMK has received consulting fees from Iovance, Merck, Bristol-Myers Squibb, Chemocentryx, Signatero, Gigagen, GI Reviewers, Pliant Therapeutics, Esai, Invox and Wherewolf, all outside of the submitted work. HK has also received research grant funding (to Yale University) from Merck, Bristol-Myers Squibb and Apexigen. MH reports—Advisory Boards: Affini-T, Exelixis, Janssen, CRISPR Therapeutics, Pliant, Regeneron, TScan; Research: Allogene, Alpine, Achilles Therapeutics, Apexigen, Arrowhead, Astellas, AstraZeneca, Bristol Myer Squibb, CRISPR Therapeutics, Eli Lilly, Lyell, Endocyte, Fate Therapeutics, Genentech, Genmab, Iovance, Merck, Novartis, Pfizer, Seattle Genetics, Synthekine, Tmunity, TScan, Xilio; Other: Arvinas, Faeth. DAB reports advisory board fees from Exelixis, AVEO, Eisai, and Elephas, equity in Elephas, Fortress Biotech (subsidiary) and CurIOS Therapeutics, consulting/personal fees from Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post/Harborside, Targeted Oncology, Merck, Pfizer, MedScape, Accolade 2nd.MD, DLA Piper, AbbVie, Compugen, Link Cell Therapies, Scholar Rock, and research support from Exelixis and AstraZeneca, outside of the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: Specimens and clinical information were collected with the approval of a Yale University Institutional Review Board.